Labcorp (LH) is expected to report Q3 2026 revenue of $3.76 billion and adjusted EPS of $4.65, with the stock currently trading at $329.10 compared to a consensus price target of $345.13.
The primary narrative for this earnings report is the organic volume growth within the Diagnostics Base Business, as investors look for evidence that recent hospital partnership wins are translating into sustainable revenue.
Analysts are also tracking the company's margin resilience in the face of ongoing Medicare reimbursement pressure under the PAMA framework.
Meanwhile, the Biopharma segment remains a significant contributor to the bottom line, benefiting from a robust backlog and high net book-to-bill ratios.